Cathay Biotech Inc.
688065.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | CN¥37,414 | CN¥33,862 | CN¥29,962 | CN¥22,585 |
| - Cash | CN¥8,106 | CN¥8,720 | CN¥10,797 | CN¥5,347 |
| + Debt | CN¥279 | CN¥543 | CN¥1,636 | CN¥1,860 |
| Enterprise Value | CN¥29,587 | CN¥25,685 | CN¥20,801 | CN¥19,099 |
| Revenue | CN¥874 | CN¥895 | CN¥776 | CN¥743 |
| % Growth | -2.3% | 15.4% | 4.4% | – |
| Gross Profit | CN¥319 | CN¥247 | CN¥261 | CN¥123 |
| % Margin | 36.5% | 27.6% | 33.6% | 16.6% |
| EBITDA | CN¥164 | CN¥187 | CN¥222 | CN¥73 |
| % Margin | 18.8% | 20.9% | 28.6% | 9.8% |
| Net Income | CN¥142 | CN¥172 | CN¥137 | CN¥144 |
| % Margin | 16.2% | 19.2% | 17.7% | 19.4% |
| EPS Diluted | 0.2 | 0.24 | 0.23 | 0.25 |
| % Growth | -16.7% | 4.3% | -8% | – |
| Operating Cash Flow | -CN¥66 | CN¥252 | CN¥87 | CN¥145 |
| Capital Expenditures | -CN¥188 | -CN¥79 | -CN¥280 | -CN¥199 |
| Free Cash Flow | -CN¥254 | CN¥173 | -CN¥192 | -CN¥54 |